Congress ctrl-Zs bulk of proposed cuts to NASA science

Congressional appropriators restored the bulk of NASA’s science funding in the FY2026 joint explanatory statement, reversing a proposed cut from a $7.33bn FY2025 enacted level to a $3.9bn request and allocating $7.25bn instead. Exploration was modestly reduced versus request ($8.31bn requested; $7.78bn allocated), but the agreement rejects terminating the Space Launch System (SLS) and Orion after Artemis III and bars diverting Artemis Moon-to-Mars transportation funds unless a commercial alternative demonstrably matches SLS/Orion. The deal reduces near-term programmatic risk for NASA contractors and stabilizes program funding, though purchasing power is still lower than prior levels, the broader bill must clear both chambers, and the planned transfer of a flown crewed “space vehicle” to Houston (widely expected to be Discovery) remains unresolved.

Analysis

Market structure: Restoring NASA science to $7.25B (vs $3.9B request and $7.33B FY25) materially reduces near‑term revenue shock to aero/defense primes and science payload suppliers; preserving SLS/Orion after Artemis III props up incumbents (BA, LMT, NOC) and delays commercial heavy‑lift adoption. Exploration trimmed to $7.78B (requested $8.31B) signals modest near‑term contract pressure but not program termination, keeping pricing power with legacy contractors for 1–3 years.

Risk assessment: Immediate risk is legislative reversal — final floor votes within 30–60 days could change allocations; mid‑term (3–12 months) risks include procurement cuts or reprogramming if commercial alternatives demonstrate parity, and long‑term (1–3 years) program cancelation if cost overruns persist. Tail risks: a surprise decision to terminate SLS or a major Artemis failure would hit BA/LMT/NOC revenue streams by >10–20% relative to current analyst forecasts; hidden dependency is commercial capability certification criteria that could shift billions quickly.

Trade implications: Tactical trade: short Boeing (BA) equity sized 2–3% of portfolio with a 3–6 month horizon (target -10–15%, stop +10%) given Starliner and execution risk despite SLS preservation. Pair trade: long Lockheed Martin (LMT) and/or Northrop Grumman (NOC) (1–2% each) funded by the BA short to capture program stability; implement via 3–9 month call spreads on LMT/NOC and a put spread on BA to cap premium spend. Expect modest spread tightening in 10Y Treasuries if defense/aerospace wins accelerate (watch for 5–15bp moves).

Contrarian angles: Consensus underestimates political volatility — markets may be underpricing the chance of later SLS termination (once commercial systems prove capability, 18–36 months). Conversely, preserving SLS could slow SpaceX/ULA pricing gains, creating opportunities in specialized suppliers (e.g., avionics, thermal systems) not in BA; historical parallel: post‑Constellation shifts benefited new commercial entrants while incumbents lagged. Unintended consequence: prolonged SLS life can inflate program costs and reduce supplier innovation, pressuring margins over multiple quarters.

Key Decisions for Investors

• Establish a 2–3% short position in BA (Boeing) equity with 3–6 month horizon; set stop‑loss at +10% and take‑profit near -12% to -15% given Starliner execution risk and political budget uncertainty.
• Implement a dollar‑neutral pair: long 1–2% LMT (Lockheed Martin) and/or NOC (Northrop Grumman) vs. equivalent BA short to capture program preservation benefits; prefer 6–9 month call spreads on LMT/NOC (buy OTM, sell higher OTM) to limit premium.
• Buy a BA 6‑month put spread (e.g., 1×1 with 3–5% OTM strikes) financed by selling a smaller amount of 6–9 month LMT/NOC OTM calls to express asymmetric downside view while keeping capital efficient.
• If final appropriations pass without material cuts (within 30–60 days), add 0.5–1% to aerospace/defense prime longs (LMT, NOC) and trim commercial launch exposure by 0.5%—reverse if funding falls >5% from $7.25B or GAO flags SLS solvency issues.
• Monitor three catalysts over next 18 months: (1) House/Senate floor votes (30–60 days), (2) Artemis II/III launch schedule and any mission delays (6–36 months), (3) formal certification of any commercial heavy‑lift that meets SLS capabilities (18–36 months); adjust positions if any catalyst shifts probability >20%.